SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened activity driven by a reported domestic chip manufacturing partnership with Apple, a catalyst that has revitalized the stock's turnaround narrative. Community discussion is polarized between optimistic investors betting on long-term structural re-rating and skeptics who view the price action as an overextended pump fueled by political headlines rather than new information.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing significant retail and institutional interest as investors anticipate a major 52-week clinical data readout for sonelokimab in hidradenitis suppurativa. Community discussion is heavily focused on the potential for a transformative valuation re-rating, with many actively debating the probability of an M&A catalyst following recent clinical progress and best-in-class performance expectations.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is seeing intense volatility and record-breaking momentum driven by a severe, multi-year supply crunch in NAND flash and enterprise SSDs, fueling a massive re-rating of the sector as institutions bet on sustained AI-driven demand. While the stock's parabolic ascent has sparked a fierce tug-of-war between retail bulls celebrating generational wealth and skeptical bears calling for an imminent correction due to extreme technical overextension.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF is experiencing intense volatility and community division, fueled by aggressive retail speculation, institutional gamma squeezes, and heated debates over the sustainability of the current AI-driven valuation cycle. Investors are actively trading between leveraged bull and bear positions, with many reacting to geopolitical headlines and potential macro shifts while debating whether current levels represent a permanent structural shift or a classic speculative blow-off top.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is drawing significant investor interest as the market anticipates potential hyperscaler lease signings tied to its pivot toward AI-focused data center and power infrastructure. The community is actively debating the stock's positioning ahead of upcoming Russell 3000 inclusion, with bulls emphasizing the company's 2.2 GW project pipeline and power-first strategy while bears express caution regarding execution risk and share dilution.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to heightened community speculation surrounding the pending 80th event milestone for the REGAL Phase 3 trial and anticipation of a potential buyout. Investors are actively debating the impact of elevated short interest, high borrow rates, and the company's progress toward late-stage commercialization.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Semiconductor stocks are experiencing intense volatility as investors weigh the rapid growth of AI-driven infrastructure demand against uncertainties surrounding upcoming Federal Reserve policy shifts. Community sentiment is deeply divided, with bulls viewing periodic pullbacks as tactical buying opportunities for leveraged exposure, while bears highlight potential overvaluation and concerns regarding institutional rotation.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors aggressively accumulate shares ahead of expected data center lease announcements in Kentucky, driven by the sector's pivot toward high-performance AI infrastructure. The community remains focused on the company's multi-gigawatt build-out potential and the high institutional interest in its capacity to secure prime, long-term power contracts.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending as investors react to a breakthrough AI-powered imaging partnership with Midjourney, which is fueling massive daily volume and intense short-squeeze speculation. While bulls are highlighting the potential for significant long-term growth driven by new semiconductor chip licensing, skeptics are expressing concerns over high volatility, potential dilution, and the company's path to consistent profitability.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending as investors respond to an analyst-backed price target increase and ongoing anticipation surrounding the company's expansion into the weight-loss peptide market. The community is actively debating the stock's momentum, with many focused on a potential short squeeze while others highlight the potential for long-term growth as the firm scales its digital health platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RELIANCE.NSE $NIFTY50.NSE  
 
📊 Reliance Q4 Earnings Comparison: 
🔹 Q4FY25 Profit: ₹19,407 Cr vs Q4FY24 Profit: ₹18,951 Cr 
🔹 Revenue: ₹2.61 Lk Cr vs ₹2.36 Lk Cr 
🔹 EBITDA: ₹48,832 Cr vs ₹42,516 Cr 
🔹 Margin: 16.8% vs 18% 
 
Growth in profit and revenue, slight dip in margin!

$NIFTY50.NSE $RELIANCE.NSE 

Reliance Q4 FY25 Snapshot:
• Net profit: ₹19,407 Cr (+2.4%)
• Revenue: ₹2,64,573 Cr (+10%)
• Jio Platforms rev: ₹39,853 Cr (+17.8%)
• ARPU: ₹206.2 vs ₹181.7 YoY
• Dividend: ₹5.5/share
Digital momentum stays strong!
#Reliance #Jio #Q4Results #ARPU #StockMarket #stocks

StockTwits for iOS

निवेश नीति

Bullish on $RELIANCE.NSE. ! Analysts See Up to 22% Upside! 🚀 
 
Following better-than-expected Q4 results, several top brokerages have revised their target prices upwards for Reliance Industries. The consensus seems strongly positive, with potential upsides ranging from 11% to a whopping 22% from Monday&#39;s closing price! #Reliance 
 
 
A closer look at the brokerage ratings reveals a lot of conviction: 
 
➡️ Jefferies: Buy, Target ₹1,660 (21.50% upside) 
➡️ CLSA: Outperform, Target ₹1,650 (20.76% upside) 
➡️ Nomura: Buy, Target ₹1,650 (20.76% upside) 
➡️ Goldman Sachs: Buy, Target ₹1,645 (20.40% upside) 
 
Analysts highlight Reliance&#39;s strong growth outlook across its various segments (oil-to-chemicals, retail, telecom), improved valuations, and the potential for further stock re-rating.  
 
$NIFTY50.NSE $NIFTYENERGY.NSE  
#brokerage #stockstowatch

StockTwits Web

The Nifty 50 is trending as investors digest a mix of institutional volatility and key IPO activity, with heavy domestic buying providing a critical buffer against persistent foreign outflows. The market remains focused on structural growth narratives in sectors like defense and technology while monitoring global developments and their impact on India's fiscal stability.

  
 
📊 Reliance Q4 Earnings Comparison: 
🔹 Q4FY25 Profit: ₹19,407 Cr vs Q4FY24 Profit: ₹18,951 Cr 
🔹 Revenue: ₹2.61 Lk Cr vs ₹2.36 Lk Cr 
🔹 EBITDA: ₹48,832 Cr vs ₹42,516 Cr 
🔹 Margin: 16.8% vs 18% 
 
Growth in profit and revenue, slight dip in margin!